Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70181 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Weijun Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Aspart, Insulin Glargine. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by β‐cell function in exploratory analyses of the Soli‐D study. Materials and Methods Soli‐D was a 24‐week, multicentre, randomised, open‐label study in Chinese adults with uncontrolled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs). We evaluated glycaemic efficacy, body weight, total insulin daily dose and hypoglycaemia outcomes with iGlarLixi versus IDegAsp by baseline fasting C‐peptide and Homeostasis Model Assessment of β‐cell function (HOMA‐β) quartile measurements.
Results
Among 386 participants, change in glycated haemoglobin (HbA1c), fasting plasma glucose or postprandial glucose at Week 24 showed no interaction with fasting C‐peptide or HOMA‐β quartile. The difference in HbA1c change favoured iGlarLixi versus IDegAsp in fasting C‐peptide quartile 1 (Q1; p = 0.045) and Q2 ( p = 0.023) and HOMA‐β Q1 ( p = 0.025). The proportion of participants with HbA1c
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
- Department of Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
- Sanofi, Shanghai, China.
- Sanofi, Beijing, China.
- Sanofi, Paris, France.
- Sanofi, Madrid, Spain.
ORCID-Profile: Weijun Gu, Xiaohong Wu, Yiming Mu
Förderung
- Sanofi
Zitieren
APA
Gu, W., Wu, X., Zhang, M., Wang, X., Du, Q., Kang, L., Lauand, F., Alvarez, A., & Mu, Y. (2026). Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70181
Vancouver
Gu W, Wu X, Zhang M, Wang X, Du Q, Kang L, et al. Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70181
BibTeX
@article{Gu2026,
author = {Gu, Weijun and Wu, Xiaohong and Zhang, Minlu and Wang, Xinyi and Du, Qin and Kang, Lei and Lauand, Felipe and Alvarez, Agustina and Mu, Yiming},
title = {Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70181}
}
EUVIMED